Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: drug development returned 18 record(s)
|
|
Sunday, 07/29/2018
|
MIDD: Perspectives and Possibilities
Dionne Price, Food and Drug Administration
2:05 PM
|
Use of Real-World in Clinical Drug Development
Xiuyu Julie Cong, Boehringer Ingelheim Pharmaceuticals Inc; Susan Wang, Boehringer Ingelheim Pharmaceuticals Inc.
3:05 PM
|
A Case Study on Model Based Meta-Analysis (MBMA) for Drug Development Decisions
Guohui Liu, Takeda Pharmaceuticals Inc ; Zhaoyang Teng, Takeda pharmaceuticals international, Co; Zhaowei Hua, Takeda Pharmaceuticals International Co.; Neeraj Gupta, Takeda pharmaceuticals international, Co; Richard Labotka, Takeda pharmaceuticals international, Co
3:35 PM
|
Practical Bayesian Modeling and Subgroup Inference in Alzheimer's Drug Development
Brad Carlin, University of Minnesota; Patrick Schnell, Ohio State University; Mark Fiecas, University of Minnesota; Peter Müller, University of Texas Austin; Qi Tang, Sanofi; Walter Offen, AbbVie
5:05 PM
|
|
Monday, 07/30/2018
|
Assessing Treatment Benefit in Patient-Centric Study Designs
Jagadish Gogate, Johnson & Johnson-Janssen R&D
|
An Application of 2-In-1 Adaptive Phase 2/3 Design for Expedited Oncology Drug Development
Xinqun (Maggie) Chen, Merck & Co., Inc.; Linda Sun, Merck & Co., Inc.; Cong Chen, Merck & Co.
2:05 PM
|
Extrapolation in Pediatric Drug Development: an Evolving Science
Yeruk Mulugeta, FDA; Lynne Yao, US FDA
2:05 PM
|
Critical Steps for Composite Endpoint Analysis
Jerry J. Li, Merck & Co., Inc.
2:20 PM
|
|
Wednesday, 08/01/2018
|
Exposure-Response Analysis with Random Forest
Zifang Guo, Merck; Thomas Jemielita, Merck & Co.; John Kang, Merck
|
Exposure-Response Analysis with Random Forest
Zifang Guo, Merck; Thomas Jemielita, Merck & Co.; John Kang, Merck
10:00 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
Bayes in Drug Development for Rare Diseases
John Scott, FDA
11:35 AM
|
|
|
